Evidence map›Paper›PMID 39333507›Full record

ArticleNature communications2024

Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining.

Yi-Chun Hsiao, Heidi Ackerly Wallweber, Robert G Alberstein, Zhonghua Lin, Changchun Du, Ainhoa Etxeberria, Theint Aung, Yonglei Shang, Dhaya Seshasayee, Franziska Seeger and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025
    Review
  6. Article
  7. Review
  8. Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yi-Chun HsiaoDepartment of Antibody Engineering, Genentech, South San Francisco, CA, 94080, USA.ORCID 0000-0003-4499-2999
Heidi Ackerly WallweberDepartment of Structural Biology, Genentech, South San Francisco, CA, USA.
Robert G AlbersteinPrescient Design, a Genentech Accelerator, South San Francisco, CA, USA.ORCID 0000-0002-6655-8811
Zhonghua LinDepartment of Antibody Engineering, Genentech, South San Francisco, CA, 94080, USA.
Changchun DuDepartment of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA.
Ainhoa EtxeberriaDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.
Theint AungDepartment of Antibody Engineering, Genentech, South San Francisco, CA, 94080, USA.
Yonglei ShangDepartment of Antibody Engineering, Genentech, South San Francisco, CA, 94080, USA.
Dhaya SeshasayeeDepartment of Antibody Engineering, Genentech, South San Francisco, CA, 94080, USA.
Franziska SeegerPrescient Design, a Genentech Accelerator, South San Francisco, CA, USA.
Andrew M WatkinsPrescient Design, a Genentech Accelerator, South San Francisco, CA, USA.
David V HansenDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.ORCID 0000-0001-9679-7189
Christopher J BohlenDepartment of Neuroscience, Genentech, South San Francisco, CA, USA.
Peter L HsuDepartment of Structural Biology, Genentech, South San Francisco, CA, USA.ORCID 0000-0002-9381-6564
Isidro HötzelDepartment of Antibody Engineering, Genentech, South San Francisco, CA, 94080, USA. ihotzel@gene.com.ORCID 0000-0001-6910-7840

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a process for rapid antibody affinity optimization by repertoire mining to identify clones across B cell clonal lineages based on convergent immune responses where antigen-specific clones with the same heavy (V

Indexed as

Antibody AffinityComplementarity Determining RegionsReceptors, ImmunologicAnimalsAntibodiesAntibodies, MonoclonalB-LymphocytesEpitopesHumansImmunoglobulin Heavy ChainsMembrane GlycoproteinsRatsAntibodiesAntibodies, MonoclonalComplementarity Determining RegionsEpitopesImmunoglobulin Heavy ChainsMembrane GlycoproteinsReceptors, Immunologic

Identifiers

PMID39333507
PMCPMC11437124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.